Caring for patients with chronic kidney disease: A joint opinion of the ambulatory care and the nephrology practice and Research Networks of the American College of Clinical Pharmacy

Pharmacotherapy

Volumn 25, Issue 1, 2005, Pages 123-143

  Zillich, Alan J ^a   Saseen, Joseph J ^b   DeHart, Renée M ^c   Dumo, Peter ^d   Grabe, Darren W ^e   Gilmartin, Cheryl ^f   Hachey, David M ^g   Hudson, Joanna Q ^h   Pruchnicki, Maria C ⁱ   Joy, Melanie S ^j  

^a PURDUE UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c SAMFORD UNIVERSITY   (United States)

^d HARPER UNIVERSITY HOSPITAL   (United States)

^e ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^g IDAHO STATE UNIVERSITY   (United States)

^h UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

ⁱ OHIO STATE UNIVERSITY   (United States)

^j UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Chronic kidney disease; Patient care; Pharmacists' role; Primary care

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMLODIPINE; AMPHOTERICIN B; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTACID AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CITRATE CALCIUM; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DEFEROXAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ERYTHROPOIETIN; GEMFIBROZIL; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; IRBESARTAN; LISINOPRIL; NONSTEROID ANTIINFLAMMATORY AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; SUCRALFATE; TACROLIMUS; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VITAMIN D;

AMBULATORY CARE; ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL PHARMACY; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSLIPIDEMIA; EARLY DIAGNOSIS; EVALUATION; HUMAN; HYPERTENSION; MEDICAL SOCIETY; OSTEODYSTROPHY; PRIMARY MEDICAL CARE; REVIEW; UNITED STATES;

AMBULATORY CARE; COMORBIDITY; EXPERT TESTIMONY; HUMANS; KIDNEY FAILURE, CHRONIC; NEPHROLOGY; PRACTICE GUIDELINES; QUALITY OF HEALTH CARE; SOCIETIES, PHARMACEUTICAL;

EID: 19944429754     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.25.1.123.55628     Document Type: Review

References (132)

1. U.S. Renal Data System. Excerpts from the USRDS 2002 annual data report: atlas of end-stage renal disease in the United States. Am J Kidney Dis 2003;41(suppl 2):S1-256.
2. U.S. Renal Data System. USRDS 2000 annual data report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2000.
3. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998;32:853-906.
4. Ferrier KE, Muhlmann MH, Baguet JP, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002;39:1020-5.
5. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney disease outcome quality initiative. Am J Kidney Dis 2002;39(suppl 1):S1-246.
6. Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999;33:1004-10.
7. National Kidney Foundation. Kidney early evaluation program. Am J Kidney Dis 2003;42(suppl 4):S1-60.
8. Attman PO, Alaupovic P, Samuelsson O. Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease. Kidney Int Suppl 1999;71:S14-17.
9. Breyer J. Diabetic nephropathy. In: Greenberg A, ed. Primer on kidney diseases, 2nd ed. San Diego: Academic Press, 1998:215-20.
10. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995;46:223-34.
11. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
12. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
13. Andersen S. Pathogenesis of hypertensive renal disease. In: Izzo JL, Black HR, eds. Hypertension primer, 2nd ed. Baltimore, MD: Lippincott, Williams and Wilkins, 1999:190-3.
14. Zarama M, Abraham PA. Drug-induced renal disease. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach, 3rd ed. Stamford, CT: Appleton and Lange, 1997:1007-32.
15. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23(suppl 2):B21-9.
16. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
17. Genuth S, Eastman R, Kahn R, et al. Implications of the United Kingdom prospective diabetes study. Diabetes Care 2003;26(suppl 1):S28-32.
18. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17.
19. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003;26(suppl 1):S33-50. (Erratum in Diabetes Care 2003;26:972.)
20. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003;26(suppl 1):S33-50. (Erratum in Diabetes Care 2003;26:972.)
21. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999;353:617-22.
22. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.
23. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH. Diabetic nephropathy. Diabetes Care 2003;26(suppl 1):S94-8.
24. American College of Endocrinology. Consensus statement on guidelines for glycemic control. Endocr Pract 2002;8(suppl 1):S5-11.
25. Klag MJ. Renal risk. In: Izzo JL, Black HR, eds. Hypertension primer, 2nd ed. Baltimore, MD: Lippincott, Williams and Wilkins, 1999:211-14.
26. Brazy PC, Stead WW, Fitzwilliam JF. Progression of renal insufficiency: role of blood pressure. Kidney Int 1989;35:670-4.
27. Oldrizzi L, Rugiu C, De Biase V, Maschio G. The place of hypertension among the risk factors for renal function in chronic renal failure. Am J Kidney Dis 1993;21:119-23.
28. Locatelli F, Marcelli D, Comelli M, et al. Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Nephrol Dial Transplant 1996;11:461-7.
29. Rosansky SJ, Hoover DR, King L, Gibson J. The association of blood pressure levels and change in renal function in hypertensive and nonhypertensive subjects. Arch Intern Med 1990;150:2073-6.
30. Lindeman RD, Tobin JD, Shock NW. Association between blood pressure and the rate of decline in renal function with age. Kidney Int 1984;26:861-8.
31. Perneger TV, Nieto FJ, Whelton PK, Klag MJ, Comstock GW, Szklo M. A prospective study of blood pressure and serum creatinine: results from the clue study and the ARIC study. JAMA 1993;269:488-93.
32. Madhavan S, Stockwell D, Cohen H, Alderman MH. Renal function during antihypertensive treatment. Lancet 1995;345:749-51.
33. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996;334:13-18.
34. Shulman NB, Ford CE, Hall WD, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: results from the hypertension detection and follow-up program. The hypertension detection and follow-up program cooperative group. Hypertension 1989;13:180-93.
35. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease: the modification of diet in renal disease study. Ann Intern Med 1995;123:754-62.
36. Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the modification of diet in renal disease study. Kidney Int 1997;51:1908-19.
37. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421-31.
38. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003;289:2560-72. (Erratum in JAMA 2003;290:197.)
39. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003;289:2560-72. (Erratum in JAMA 2003;290:197.)
40. Abosaif NY, Arije A, Atray NK, et al. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43(suppl 1):S1-290.
41. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH. Progression of diabetic nephropathy. Kidney Int 2001;59:702-9.
42. The ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288:2981-97.
43. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type 11 diabetic patients. Ann Intern Med 1993;118:577-81.
44. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001;134:370-9.
45. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
46. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group. N Engl J Med 1993;329:1456-62.
47. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.
48. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857-63.
49. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med 2001;135:73-87.
50. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The angiotensin-converting-enzyme inhibition in progressive renal insufficiency study group. N Engl J Med 1996;334:939-45.
51. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
52. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
53. Zillich AJ, Carter BL. Eplerenone: a novel selective aldosterone blocker. Ann Pharmacother 2002;36:1567-76.
54. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4.
55. McAlister FA, Zarnke KB, Campbell NR, et al. The 2001 Canadian recommendations for the management of hypertension. II. Therapy. Can J Cardiol 2002;18:625-41.
56. Ramsay LE, Williams B, Johnston GD, et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999;319:630-5.
57. Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis 2001;37:484-9.
58. Tonelli M, Moye L, Sacks FM, Kiberd B, Curhan G. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003;138:98-104.
59. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
60. National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis 2003;41(suppl 3):S1-92.
61. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003;14:1605-13.
62. Crook ED, Thallupureddy A, Migdal S, et al. Lipid abnormalities and renal disease: is dyslipidemia a predictor of progression of renal disease? Am J Med Sci 2003;325:340-8.
63. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003;41:565-70.
64. Owada A, Suda S, Hata T. Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial. Am J Med 2003;114:347-53.
65. Gheith OA, Sobh MA, Mohamed Kel S, et al. Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron 2002;91:612-19.
66. van Dijk MA, Kamper AM, van Veen S, Souverijn JH, Blauw GJ. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2001;16:2152-7.
67. Nakamura T, Ushiyama C, Hirokawa K, et al. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol Dial Transplant 2002;17:798-802.
68. Nakamura T, Ushiyama C, Hirokawa K, Osada S, Shimada N, Koide H. Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol 2001;21:449-54.
69. Imai Y, Suzuki H, Saito T, Tsuji I, Abe K, Saruta T. The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia. Pravastatin and renal function research group. Clin Exp Hypertens 1999;21:1345-55.
70. Tonolo G, Ciccarese M, Brizzi P, et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 1997;20:1891-5.
71. Zhang A, Vertommen J, Van Gaal L, De Leeuw I. Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients. Diabetes Res Clin Pract 1995;29:189-94.
72. Lam KS, Cheng IK, Janus ED, Pang RW. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995;38:604-9.
73. Hommel E, Andersen P, Gall MA, et al. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia 1992;35:447-51.
74. Sasaki T, Kurata H, Nomura K, Utsunomiya K, Ikeda Y. Amelioration of proteinuria with pravastatin in hypercholesterolemic patients with diabetes mellitus. Jpn J Med 1990;29:156-63.
75. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001;59:260-9.
76. Halimi JM, Giraudeau B, Vol S, et al. Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Int 2000;58:1285-92.
77. Pinto-Sietsma SJ, Mulder J, Janssen WM, Hillege HL, de Zeeuw D, de Jong PE. Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med 2000;133:585-91.
78. Orth SR. Smoking and the kidney. J Am Soc Nephrol 2002;13:1663-72.
79. Gerstein HC, Mann JF, Pogue J, et al. Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the heart outcomes prevention evaluation study. The HOPE study investigators. Diabetes Care 2000;23(suppl 2):B35-9.
80. Fiore MC. U.S. Public Health Service clinical practice guideline: treating tobacco use and dependence. Respir Care 2000;45:1200-62.
81. Tomar SL, Husten CG, Manley MW. Do dentists and physicians advise tobacco users to quit? J Am Dent Assoc 1996;127:259-65.
82. Woller SC, Smith SS, Piasecki TM, et al. Are clinicians intervening with their patients who smoke? A "real-world" assessment of 45 clinics in the upper Midwest. Wis Med J 1995;94:266-72.
83. Goldstein MG, Niaura R, Willey-Lessne C, et al. Physicians counseling smokers: a population-based survey of patients' perceptions of health care provider-delivered smoking cessation interventions. Arch Intern Med 1997;157:1313-19.
84. Cooper TM, Clayton RR. Nicotine reduction therapy and relapse prevention for heavy smokers: 3-year follow-up. J Am Dent Assoc 1990;Jan(suppl):S32-6.
85. Kennedy DT, Giles JT, Chang ZG, Small RE, Edwards JH. Results of a smoking cessation clinic in community pharmacy practice. J Am Pharm Assoc 2002;42:51-6.
86. Zillich AJ, Ryan M, Adams A, Yeager B, Farris K. Effectiveness of a pharmacist-based smoking-cessation program and its impact on quality of life. Pharmacotherapy 2002;22:759-65.
87. Molander L, Hansson A, Lunell E, Alainentalo L, Hoffmann M, Larsson R. Pharmacokinetics of nicotine in kidney failure. Clin Pharmacol Ther 2000;68:250-60.
88. GlaxoSmithKline Pharmaceuticals. Zyban (bupropion hydrochloride) package insert. Research Triangle Park, NC; 2004. Available from http://www.gsk.com/ products/assets/us_zyban.pdf. Accessed June 19, 2003.
89. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the third national health and nutrition examination survey. J Am Soc Nephrol 2002;13:504-10.
90. Owen WF Jr. Patterns of care for patients with chronic kidney disease in the United States: dying for improvement. J Am Soc Nephrol 2003;14:S76-80.
91. Radtke HW, Claussner A, Erbes PM, Scheuermann EH, Schoeppe W, Koch KM. Serum erythropoietin concentration in chronic renal failure: relationship to degree of anemia and excretory renal function. Blood 1979;54:877-84.
92. Jungers PY, Robino C, Choukroun G, Nguyen-Khoa T, Massy ZA, Jungers P. Incidence of anaemia and use of epoetin therapy in pre-dialysis patients: a prospective study in 403 patients. Nephrol Dial Transplant 2002;17:1621-7.
93. Foley RN. Anaemia: cardiovascular adaptations and maladaptive responses in chronic kidney disease. Nephrol Dial Transplant 2002;17(suppl 11):32-4.
94. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996;27:347-54.
95. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995;47:186-92.
96. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53-61.
97. Moreno F, Aracil FJ, Perez R, Valderrabano F. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. Am J Kidney Dis 1996;27:548-56.
98. Stivelman JC. Benefits of anaemia treatment on cognitive function. Nephrol Dial Transplant 2000;15(suppl 3):29-35.
99. Evans RW, Rader B, Manninen DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative multicenter EPO clinical trial group. JAMA 1990;263:825-30.
100. National Kidney Foundation. K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001;37(suppl 1):S182-238.
101. Valderrabano F, Horl WH, Macdougall IC, Rossert J, Rutkowski B, Wauters JP. Pre-dialysis survey on anaemia management. Nephrol Dial Transplant 2003;18:89-100.
102. Joy MS. Darbepoetin alfa: a novel erythropoiesis-stimulating protein. Ann Pharmacother 2002;36:1183-92.
103. Singbartl G. Adverse events of erythropoietin in long-term and in acute/short-term treatment. Clin Investig 1994;72:S36-43.
104. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17.
105. Keith DS. Re-evaluating our approach to calcium and phosphorus management in dialysis patients. Am J Kidney Dis 2001;37:1331-3.
106. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-8.
107. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001;38:938-42.
108. Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients: a link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002;39:695-701.
109. Eknoyan G, Levin A, Levin NW, for the National Kidney Foundation. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(suppl 3):1-201.
110. U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2001;136(2):157-60.
111. Bridges CB, Harper SA, Fukuda K, Uyeki TM, Cox NJ, Singleton JA. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2003;52(RR-8):1-34.
112. Anonymous. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997;46(RR-8):1-24.
113. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999;130:461-70.
114. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
115. Borenstein JE, Graber G, Saltiel E, et al. Physician-pharmacist comanagement of hypertension: a randomized, comparative trial. Pharmacotherapy 2003;23:209-16.
116. Solomon DK, Portner TS, Bass GE, et al. Clinical and economic outcomes in the hypertension and COPD arms of a multicenter outcomes study. J Am Pharm Assoc 1998;38:574-85.
117. Sadur CN, Moline N, Costa M, et al. Diabetes management in a health maintenance organization: efficacy of care management using cluster visits. Diabetes Care 1999;22:2011-17.
118. Kelley KW, Ramsey LA, Rochester CD, Hood EH, Harrell TK. Management of type 2 diabetes: comparison of a specialty clinic and an internal medicine resident clinic. Presented at the 36th annual American Society of Health-System Pharmacists midyear clinical meeting, New Orleans, LA, December 2-6, 2001.
119. Wong T, Foote EF, Lefavour GS, Cody RP, Brown CJ, Sherman RA. Physician knowledge and practice patterns relating to diabetic nephropathy. J Am Pharm Assoc 1999;39:785-90.
120. Silverberg DS, Wexler D, Blum M, et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003;18:141-6.
121. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997;77:176-85.
122. London R, Solis A, Goldberg GA, Wade S, Ryu S. Health care resource utilization and the impact of anemia management in patients with chronic kidney disease. Am J Kidney Dis 2002;40:539-48.
123. To LL, Stoner CP, Stolley SN, Buenviaje JD, Ziegler TW. Effectiveness of a pharmacist-implemented anemia management protocol in an outpatient hemodialysis unit. Am J Health-Syst Pharm 2001;58:2061-5.
124. Ueoka J, DiBernardo JD, Calescibetta CC, Hill TR. Pharmacist managed subcutaneous erythropoietin dose adjustment program in an outpatient hemodialysis unit. Presented at the 35th annual American Society of Health-System Pharmacists midyear clinical meeting, Las Vegas, NV, December 8-12, 2000.
125. Buenviaje JD, To LL, Stoner CP, Stolley SN, Ziegler TW. Pilot study of an anemia management protocol at VA San Diego Healthcare System. Presented at the 35th annual American Society of Health-System Pharmacists midyear clinical meeting, Las Vegas, NV, December 8-12, 2000.
126. Qin M, Patel PB, Each DS. Impact of pharmacy services in the end-stage renal disease patient. Presented at the 33rd annual American Society of Health-System Pharmacists midyear clinical meeting, Las Vegas, NV, December 6-10, 1998.
127. Anonymous. Pharmacist-run program optimally manages secondary hyperparathyroidism. Formulary 1998;33:1217-18.
128. Paris W, Dunham S, Sebastian A, Jacobs C, Nour B. Medication nonadherence and its relation to financial restriction. J Transpl Coord 1999;9:149-52.
129. Lowe CJ, Raynor DK, Purvis J, Farrin A, Hudson J. Effects of a medicine review and education programme for older people in general practice. Br J Clin Pharmacol 2000;50:172-5.
130. Williford SL, Johnson DF. Impact of pharmacist counseling on medication knowledge and compliance. Mil Med 1995;160:561-4.
131. Cleary DJ, Matzke GR, Alexander AC, Joy MS. Medication knowledge and compliance among patients receiving long-term dialysis. Am J Health-Syst Pharm 1995;52:1895-900.
132. Weiner S, Dischler J, Horvitz C. Beyond pharmaceutical manufacturer assistance: broadening the scope of an indigent drug program. Am J Health-Syst Pharm 2001;58:146-50.